European Journal of Clinical Microbiology & Infectious Diseases最新文献

{"title":"Burden of syphilis among people living with HIV: a large cross-sectional study from Türkiye.","authors":"Selim Merdan, Yağmur Ekenoğlu Merdan, Okan Aydoğan","doi":"10.1007/s10096-025-05199-1","DOIUrl":"https://doi.org/10.1007/s10096-025-05199-1","url":null,"abstract":"<p><strong>Background: </strong>Syphilis and HIV are closely linked infections with shared transmission routes and risk factors. Despite effective screening and treatment options, the prevalence of syphilis remains high among people living with HIV (PLWH), especially in middle-income countries like Türkiye.</p><p><strong>Objectives: </strong>To investigate the seroprevalence of syphilis among PLWH using centralized laboratory data and to assess its distribution by age and sex.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted by reviewing data derived from blood specimens submitted to our laboratory for routine CD4⁺ T cell enumeration, ultimately analyzing 2,768 PLWH between January 2022 and December 2024. Syphilis seropositivity was defined by concurrent positivity in both VDRL and TPHA tests. Demographic and clinical variables were analyzed using SPSS v.22.0.</p><p><strong>Results: </strong>Syphilis seropositivity was detected in 923 patients (33.3%). The prevalence was significantly higher among males (37.0%) compared to females (6.1%) (p < 0.001). The highest seroprevalence was observed in patients aged 31-40 years (37.4%). There was no significant difference in mean age between syphilis-positive and syphilis-negative groups (p > 0.05).</p><p><strong>Conclusion: </strong>This study reveals a high burden of syphilis among PLWH in Türkiye, particularly in younger male populations. The findings underscore the necessity for routine syphilis screening, targeted prevention strategies, and integrated STI care within HIV programs.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence trends and epidemiology of invasive device-associated bacteremia in French nursing home residents, 2020-2024: Insights from the SPIADI Prospective Multicenter Study.","authors":"Maris Dussartre, Nicolas Duflot, Anne-Sophie Valentin, Mathilde Farizon, Florent Goube, Nathalie van der Mee-Marquet","doi":"10.1007/s10096-025-05188-4","DOIUrl":"10.1007/s10096-025-05188-4","url":null,"abstract":"<p><p>Healthcare-associated bacteremia is associated with increased morbidity and mortality. In nursing homes, these infections remain under-documented. We investigated invasive device-associated bacteremia in residents. We analyzed bacteremias acquired in nursing homes using data from a national surveillance program conducted between 2020 and 2024, involving 1,233 French healthcare institutions. A total of 2,117 bacteremias acquired in the nursing home were recorded. The main sources of infection were the urinary tract (52.1%) and the respiratory tract (11.9%). An invasive device was involved in 20.0% of cases, primarily urinary catheters (386 cases), while bacteremia related to intravascular devices was rare (38 cases). Enterobacterales (64.0%) and Staphylococcus aureus (14.6%) were the most frequently identified pathogens, with multidrug-resistant bacteria detected in 15.2% of nursing home-acquired bacteremias. The incidence rate was 0.009 per 1,000 resident-days, remaining stable over the study period. The study highlights the burden of bacteremias in nursing homes and underscores the importance of targeted infection prevention measures, particularly in relation to urinary catheter management, and long-term intravascular central lines.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A European survey on anaerobes from paediatric blood cultures: a comparative analysis with adults.","authors":"Matteo Boattini, Arianna Aceti, Paulo Bastos, Viktoria Eirini Mavromanolaki, Sofia Maraki, Anastasia Spiliopoulou, Vasileios Kakouris, Yordan Kalchev, Ana Budimir, Branka Bedenić, Zana Rubic, Monica Licker, Corina Musuroi, Emese Juhász, Katalin Kristóf, Mateja Pirs, Ivana Velimirovic, Michael Berktold, Adriána Liptáková, Adriana Krajčíková, Pavel Drevinek, Anezka Gryndlerova, Monika Brzychczy-Wloch, Aldona Olechowska-Jarząb, Filip Bielec, Małgorzata Brauncajs, Edyta Podsiadly, Grażyna Nurzyńska, Patrycja Zalas-Więcek, Anna Michalska, Kristian Riesbeck, Hanna-Sofia Andersson, Tone Tønjum, Johan Christian Berild, Truls Michael Leegaard, Asger Nellemann Rasmussen, Kristian Schønning, Stefan Glöckner, Jürgen Rödel, Mohamed Tarek Badr, Georg Alexander Häcker, Denise Stark, Axel Hamprecht, Anna Dudakova, Jonathan Jantsch, Stefano Mancini, Chantal Quiblier, Damien Jacot, Gilbert Greub, Tiziano Ferniani, Simone Ambretti, Maddalena Calvo, Stefania Stefani, Rogier Schade, Erlangga Yusuf, Stefanie van Kleef-van Koeveringe, Sarah Vandamme, Alexia Verroken, Hector Rodriguez-Villalobos, François Duigou, Stéphane Corvec, Pauline Floch, Clémence Massip, Delphine Chainier, Olivier Barraud, Marie-Bossuète Louissaint, Assaf Mizrahi, Saied Ali, Maeve Doyle, Clarice Egan, Sinead McNicholas, Javier Colomina-Rodriguez, Ignacio Torres, Raul Gillaranz Luengo, Maria Nieves Larrosa Escartín, Maria Belen Viñado Perez, Ana Verónica Halperin, Sergio Fuente García, Rafael Cantón, Miguel Seruca, Vasco Santos Mendes, Dinah Carvalho, Rossana Cavallo, José Melo Cristino, Cristina Costa, Gabriele Bianco","doi":"10.1007/s10096-025-05185-7","DOIUrl":"10.1007/s10096-025-05185-7","url":null,"abstract":"<p><p>Infections caused by anaerobes are common in children. However, limited data are available on bloodstream infections caused by these bacteria in Europe. A multicentre retrospective observational study was conducted over a 4-year period (2020-2023) across 44 European hospitals to analyze all anaerobes isolated from blood cultures. The study examined the epidemiology and antimicrobial resistance profiles of anaerobes identified in paediatric patients, comparing the findings with those observed in adults. Among the 14,527 total anaerobic isolates, 186 (1.3%) were detected from paediatric patients. These were predominantly Gram-positive (70%) and Gram-negative (22%) bacilli. The most prevalent species in paediatric patients were Cutibacterium acnes (24.7%), Schaalia odontolytica (9.7%), Actinomyces oris (8.1%), and Bacteroides fragilis (7.5%). Relative feature importance based on the mean SHAP (SHapley Additive exPlanations) values distinguished paediatric patients and adults based on their antibiotic resistance patterns with high accuracy. Compared to those from adult patients, Gram-positive bacilli detected in paediatric samples displayed higher resistance rates for meropenem (15% vs. 9%), metronidazole (52% vs. 24%), and vancomycin (27% vs. 6%), and lower resistance to benzylpenicillin (11% vs. 17%), amoxicillin/clavulanate (9% vs. 17%), and clindamycin (30% vs. 36%). Gram-negative bacilli in paediatric samples displayed lower resistance to benzylpenicillin (18% vs. 29%), piperacillin/tazobactam (26% vs. 33%), and clindamycin (20% vs. 27%), and they were highly susceptible to imipenem, meropenem, and metronidazole as those detected in adult patients. Bacteroides species detected in paediatric and adult patients displayed high resistance to piperacillin/tazobactam (33% vs. 39%) and clindamycin (38% vs. 29%), while they were highly susceptible to metronidazole. Compared to those from adult samples, Cutibacterium acnes in paediatric patients displayed lower resistance to benzylpenicillin (none vs. 15%) and clindamycin (17% vs. 29%). The comparison of species and susceptibility profiles of anaerobes detected in paediatric and adult patients highlighted the importance of reporting antimicrobial susceptibility surveillance data by age group.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of ceftazidime-avibactam resistance in clinical Klebsiella pneumoniae during therapy.","authors":"Siquan Shen, Xiren Deng, Lu Guo, Li Yang, Hua Yu, Fupin Hu, Xiangning Huang","doi":"10.1007/s10096-025-05180-y","DOIUrl":"https://doi.org/10.1007/s10096-025-05180-y","url":null,"abstract":"<p><strong>Background: </strong>The emergence of ceftazidime-avibactam resistance in Klebsiella pneumoniae poses a significant public health threat, driven by mutations in the bla . This study investigates the evolution of KPC variants (KPC-33, KPC-84, KPC-190) during therapy, highlighting their impact on resistance profiles and treatment challenges. Understanding these mechanisms is critical for guiding clinical interventions.</p><p><strong>Methods: </strong>Four K. pneumoniae strains were isolated from a patient undergoing ceftazidime-avibactam therapy. Antimicrobial susceptibility testing and bioinformatics tools were used to characterize genetic mutations and their phenotypic effects. Whole genome sequencing, cloning, and enzymatic kinetic assays were performed to analyze resistance mechanisms.</p><p><strong>Results: </strong>The study identified mutations in the Ω-loop and 240-loop of KPC-2, leading to reduced avibactam affinity and increased ceftazidime hydrolysis. KPC-33 restored carbapenem susceptibility, while KPC-84 and KPC-190 conferred dual resistance. Enzymatic assays confirmed altered kinetic parameters, correlating with clinical resistance patterns.</p><p><strong>Conclusions: </strong>KPC variants exhibit complex evolutionary pathways under antibiotic pressure, complicating treatment. Enhanced surveillance and optimized dosing regimens, including higher avibactam concentrations, are recommended to mitigate resistance. This study underscores the need for global monitoring of KPC variants to inform therapeutic strategies.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-wide Screening of the Escherichia coli Keio Knockout Collection Identifies Genetic Determinants of Epetraborole Hypersusceptibility.","authors":"Anara Babayeva, Bekir Çöl","doi":"10.1007/s10096-025-05183-9","DOIUrl":"https://doi.org/10.1007/s10096-025-05183-9","url":null,"abstract":"<p><strong>Purpose: </strong>The escalating threat of antibiotic resistance necessitates innovative strategies to enhance the efficacy of emerging antimicrobials. Epetraborole (EP) is a boron-containing antibiotic targeting leucyl-tRNA synthetase (LeuRS) and has attracted interest for its novel mechanism of action and potential to treat infections caused by multidrug-resistant (MDR) Gram-negative pathogens.</p><p><strong>Methods: </strong>To elucidate the genetic determinants of EP susceptibility, we conducted a genome-wide screen (GWS) of the Escherichia coli Keio knockout collection, which comprises ~4,000 single-gene deletion mutants. Mutants exhibiting increased susceptibility to epetraborole were identified and validated via complementation assays.</p><p><strong>Results: </strong>Disrupted genes included those involved in leucine biosynthesis (leuD), RNA turnover (rnb), tRNA modification (trmU), ubiquinone biosynthesis (ubiG), NAD salvage pathway (pncA), arginine transport (artJ), transcriptional regulator (yddM) and ribosome biogenesis (yhbY), suggesting that epetraborole's primary inhibition of LeuRS synergizes with defects in these pathways. Bioinformatic analyses (Omics Dashboard, DAVID, STRING) linked these genes to tRNA homeostasis, stress response networks, and central dogma processes, implicating tRNA dysregulation as a critical vulnerability under epetraborole-induced stress.</p><p><strong>Conclusion: </strong>This study identifies novel genetic contributors to epetraborole susceptibility and provides a framework for exploring adjuvant therapies or resistance mechanisms to enhance its clinical utility against MDR infections.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rash associated with antibiotic administration in patients with infectious mononucleosis: a systematic review and meta-analysis.","authors":"Christos Vrysis, Angeliki Katsarou, Theodore Lytras, Konstantinos Katsikas, Matthew E Falagas","doi":"10.1007/s10096-025-05189-3","DOIUrl":"https://doi.org/10.1007/s10096-025-05189-3","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Underutilization of nirmatrelvir/ritonavir in eligible COVID-19 patients.","authors":"Celia Fortea de Arpe, Reynaldo Homen, Adrian Valls-Carbó, Julia Barrado, Carolina Olmos-Mata, Juncal Pérez-Somarriba, Ana Muñoz-Gomez, Maria Jose Núñez-Orantos, Noemí Cabello-Clotet, Vicente Estrada","doi":"10.1007/s10096-025-05150-4","DOIUrl":"https://doi.org/10.1007/s10096-025-05150-4","url":null,"abstract":"<p><p>Nirmatrelvir/ritonavir (NMV/r) might reduce the risk of hospitalization or death due to SARS-CoV2. Indirect data suggest that antiviral use among non-hospitalized patients is low. The aim of the study is to determine the number of patients admitted for COVID-19 who met the criteria to receive NMV/r prior to admission but did not receive it. We analyzed clinical data from electronic medical records of 132 patients who were hospitalized due to Covid-19 from August to November 2023. Among the 88 patients eligible for NMV/r before hospitalization, only 3.8% received it, even though 24.3% had previous contact with the healthcare system. Among those who were eligible for treatment, a potential drug interaction was identified in 80.6%; NMV/r was contraindicated in only ten cases (11.3%) due to a serious interaction, as it was deemed impossible to stop or alter it. Of the patients who did not receive treatment, three died from Covid-19, while there were no deaths in the treatment group. Our data confirm that many patients who could benefit from early treatment with NMV/r are not receiving it. This limited use may be linked to missed opportunities to prevent hospitalization and mortality from Covid-19.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic drug monitoring in patients treated with vancomycin: a single center, prospective, observational, real-world study.","authors":"Cansu Zeynep Dogan, Emre Kara, Asli Pinar, Kutay Demirkan, Gokhan Metan","doi":"10.1007/s10096-025-05182-w","DOIUrl":"https://doi.org/10.1007/s10096-025-05182-w","url":null,"abstract":"<p><strong>Purpose: </strong>Therapeutic drug monitoring of vancomycin targeting an AUC/MIC ratio of 400-650 mg*h/L is required to ensure optimal therapeutic efficacy and safety in patients treated with vancomycin. The objectives of this study were to monitor vancomycin plasma peak and trough concentrations to calculate the area under the curve (AUC) to assess target achievement in real-world settings and to evaluate the relationship between AUC and acute kidney injury (AKI).</p><p><strong>Methods: </strong>In this single-center cohort study, prospectively calculated vancomycin AUC and trough concentrations were extracted from the database and evaluated for achievement of therapeutic ranges for AUC and trough concentrations at a university hospital. Patients were evaluated for the development of AKI according to KDIGO guidelines.</p><p><strong>Results: </strong>A total of 114 patients were included in the study. Vancomycin loading doses were initiated in 83.3% of patients, and 82.1% of patients received the appropriate weight-based dose. 79.8% of maintenance doses were appropriate. The median (min-max) values for peak, trough, and AUC were 23.25 (3.3-131.8) mg/L, 10.35 (0.6-56.4) mg/L, and 403(49-1786) mg/L*hour, respectively. The majority of values were outside the therapeutic target for both trough (65.3%) and AUC (63.7%). AKI was observed in 15.8% of patients. In patients without AKI, the median (min-max) trough concentration was 9.65 (0.60-45.30) mg/L and the AUC was 370 (49-1390) mg/L*hour.</p><p><strong>Conclusions: </strong>In this study, only one-third of baseline concentrations were in the therapeutic range and were increased by up to two-thirds with dose adjustments. Therapeutic drug monitoring to achieve target concentrations is critical in patients treated with vancomycin.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic-related dysbiosis of gut microbiota in healthy volunteers: a comparative study of ceftazidime-avibactam, piperacillin-tazobactam, and ceftriaxone.","authors":"Guohang Huang, Lili Cai, Jinlin Guo, Ruyi Zhu, Lina Zhu","doi":"10.1007/s10096-025-05184-8","DOIUrl":"https://doi.org/10.1007/s10096-025-05184-8","url":null,"abstract":"<p><p>The administration of antibiotics can induce gut microbiota dysbiosis leading to Clostridium difficile infection and has been linked to conditions such as irritable bowel syndrome and metabolic syndrome. However, the specific effects of different antibiotics on the gut microbiota composition remain poorly characterized, particularly in human studies. A previous published phase I study explored the role of a colon-targeted adsorbent DAV132 to mitigate the effects of antibiotics-related dysbiosis on the gut microbiota in healthy individuals. Using the publicly available dataset from this publication PRJNA922086, we evaluated the impacts of a 5-day intravenous treatment with two broad-spectrum beta-lactam/beta-lactamase inhibitor antibiotics ceftazidime-avibactam, piperacillin-tazobactam and a third-generation cephalosporin ceftriaxone on the diversity, composition, and bacterial interactions at days 1, 6, and 37 post-administration. All three antibiotics significantly altered beta diversity of the gut microbiota by day 6, with ceftriaxone exhibiting the most prolonged effects. Changes in the composition of the gut microbiota were more similar between the ceftazidime-avibactam and piperacillin-tazobactam groups, and distinct from those observed in the ceftriaxone group. Consistent with beta diversity changes, bacterial interaction networks revealed greater and longer-lasting disruptions of bacterial interaction in the gut microbiota in the ceftriaxone group compared to the other two antibiotics. These findings highlight distinct patterns of microbiota disruption following ceftriaxone, ceftazidime-avibactam, and piperacillin-tazobactam treatments and underscore the importance of antibiotic selection in minimizing gut dysbiosis.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a real-time multiple cross displacement amplification assay for rapid and highly sensitive detection of Streptococcus pyogenes.","authors":"Yiqin Zhang, Xinbei Jia, Lijuan Ma, Lin Zhou, Fei Xiao, Xiaolan Huang, Juan Zhou, Yi Wang, Jun Tai","doi":"10.1007/s10096-025-05186-6","DOIUrl":"https://doi.org/10.1007/s10096-025-05186-6","url":null,"abstract":"<p><p>The aim of this study was to develop a method based on multiple cross displacement amplification (MCDA) and real-time fluorescence technique for rapid, highly sensitive and specific detection of Streptococcus pyogenes (Group A Streptococcus, GAS). A set of 10 primers targeting the speB gene of GAS was designed for the MCDA reaction. According to the principle of real-time MCDA detection, the core primer was further modified with a restriction endonuclease recognition sequence, a fluorophore, and a quencher. The optimal reaction temperature for the assay was determined based on the performance of the MCDA amplification products. The detection limit was evaluated using tenfold serial dilutions of GAS genomic DNA templates. To assess specificity, the assay was tested using genomic DNA from 3 GAS strains and 29 non-GAS strains. To evaluate clinical application of the GAS real-time MCDA assay, 56 clinical samples were analyzed and compared with the lateral flow biosensors (LFB) method and PCR. The GAS real-time MCDA method was performed using a fluorescence instrument at 63℃ for 40 min. The method demonstrated high sensitivity, with a detection limit of 50 fg, and showed no cross-reactivity with other pathogens. The GAS real-time MCDA assay described here offers a new and valuable diagnostic tool for the reliable and rapid detection of GAS.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}